Page 112 - 《中国药科大学学报》2025年第5期

644 学报 Journal of China Pharmaceutical University 2025, 56(5): 634 − 644 第 56 卷

2015, 407(16): 4683-4695. [26] DeVore NM, Scott EE. Structures of cytochrome P450 17A1
[18] Hanna AY, Abbas H, Yassine F, et al. Systematic review of gut with prostate cancer drugs abiraterone and TOK-001[J]. Nature,
microbiota composition, metabolic alterations, and the effects of 2012, 482(7383): 116-119.
treatments on PCOS and gut microbiota across human and ani- [27] Grimshaw RN, Mitchell BF, Challis JR. Steroid modulation of
mal studies[J]. Front Microbiol, 2025, 16: 1549499. pregnenolone to progesterone conversion by human placental
[19] Yu Y, Tan PL, Zhuang ZC, et al. Untargeted metabolomic ap- cells in vitro[J]. Am J Obstet Gynecol, 1983, 145(2): 234-238.
proach to study the serum metabolites in women with polycys- [28] Vanweert F, Schrauwen P, Phielix E. Role of branched-chain
tic ovary syndrome[J]. BMC Med Genomics, 2021, 14(1): 206. amino acid metabolism in the pathogenesis of obesity and type
[20] Salilew-Wondim D, Wang Q, Tesfaye D, et al. Polycystic ovari- 2 diabetes-related metabolic disturbances BCAA metabolism in
type 2 diabetes[J]. Nutr Diabetes, 2022, 12(1): 35.
an syndrome is accompanied by repression of gene signatures
[29] Kogot-Levin A, Riahi Y, Abramovich I, et al. Mapping the
associated with biosynthesis and metabolism of steroids, choles-
metabolic reprogramming induced by sodium-glucose cotrans-
terol and lipids[J]. J Ovarian Res, 2015, 8: 24.
porter 2 inhibition[J]. JCI Insight, 2023, 8(7): e164296.
[21] Cho LW, Sathyapalan T, Kilpatrick ES, et al. Androsterone glu-
[30] Wang M, Zhang BQ, Ma S, et al. Broadening horizons: the role
curonide to dehydroepiandrosterone sulphate ratio is discrimina-
of ferroptosis in polycystic ovary syndrome[J]. Front En-
tory for obese Caucasian women with polycystic ovary syn-
docrinol (Lausanne), 2024, 15: 1390013.
drome[J]. BMC Endocr Disord, 2017, 17(1): 26.
[31] Tian Y, Zhang W, Zhao SG, et al. FADS1-FADS2 gene cluster
[22] Wang KX, Li YH, Chen Y. Androgen excess: a hallmark of
confers risk to polycystic ovary syndrome[J]. Sci Rep, 2016, 6:
polycystic ovary syndrome[J]. Front Endocrinol (Lausanne),
21195.
2023, 14: 1273542.
[32] Olaniyi KS, Okara DO, Areloegbe SE. Suppression of adipose
[23] Dong JW, Aled Rees D. Polycystic ovary syndrome: pathophys-
TGF-β1 by probiotics alleviates metabolic disturbance in exper-
iology and therapeutic opportunities[J]. BMJ Med, 2023, 2(1):
imentally induced PCOS[J]. Prostaglandins Other Lipid Medi-
e000548. at, 2025, 178: 106989.
[24] Armstrong CM, Gao AC. Dysregulated androgen synthesis and [33] Zhang WY, Wu FJ. Linoleic acid induces human ovarian granu-
anti-androgen resistance in advanced prostate cancer[J]. Am J losa cell inflammation and apoptosis through the ER-FOXO1-
Clin Exp Urol, 2021, 9(4): 292-300. ROS-NFκB pathway[J]. Sci Rep, 2024, 14(1): 6392.
[25] Giatromanolaki A, Fasoulaki V, Kalamida D, et al. CYP17A1 [34] Puchałowicz K, Rać ME. The multifunctionality of CD36 in di-
and androgen-receptor expression in prostate carcinoma tissues abetes mellitus and its complications-update in pathogenesis,
and cancer cell lines[J]. Curr Urol, 2019, 13(3): 157-165. treatment and monitoring[J]. Cells, 2020, 9(8): 1877.